BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

BOSTON, Nov. 7, 2018 /PRNewswire/ -- BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced four abstracts showcasing the value of its Back to Biology approach in identifying disease signatures and mechanisms of Parkinson's disease (PD) and other neurological disorders were presented at the annual meeting of the Society for Neuroscience (SfN) in San Diego, California, Nov. 3-7, 2018.

Cognitive decline and alterations in motor coordination are some of the earliest symptoms detected in patients with mild cognitive impairments or Parkinson's disease, respectively, and enhanced understanding of molecular pathways surrounding these has the potential to greatly improve translation of preclinical research toward therapeutic and diagnostic development. BERG's proprietary Interrogative Biology platform and bAIcis artificial intelligence (AI) tool utilize multi-omic profiling and represent one of the most robust platforms for the diagnosis, prognosis and understanding of neurological diseases.

Key presentation highlights include:

• Pre-clinical data identifying promising molecules and pathways as target candidates for major depressive disorder.
• Pre-clinical metabolic signaling data with potential to distinguish between age-related changes in the brain and age-related cognitive decline in Alzheimer's disease.
• In vitro data suggesting mechanistic link between leucine-rich repeat kinase 2 (LRRK2), p53 inducible gene 3 (PIG3) and PD-related neurodegeneration.
• Neurometabolomic and phenotype data supportive of PIG3 as a novel therapeutic target in PD-specific pathologies.

"BERG is leading the way in discovering new therapeutic targets to treat Parkinson's disease and other neurological disorders by identifying critical links in the neurodegeneration process utilizing our Interrogative Biology platform and AI-driven research into the pathology of disease," said Niven R. Narain, Ph.D., BERG Co-founder, President and Chief Executive Officer. "Our Back to Biology approach has further identified novel profiles driving disease activity – such as LRRK2 mutation and PIG3 expression – that we believe hold great potential for novel treatments for patients suffering from progressive, debilitating neurodegenerative disorders."